2020
Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study
Zhang Q, Cai Y, Kurbatov V, Khan SA, Lu L, Zhang Y, Johnson CH. Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International 2020, 2020: 8826456. PMID: 33415160, PMCID: PMC7769650, DOI: 10.1155/2020/8826456.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAgedAlpha-Ketoglutarate-Dependent Dioxygenase FTOColorectal NeoplasmsDatabases, GeneticDisease-Free SurvivalDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMaleMultivariate AnalysisMutationNerve Tissue ProteinsPrognosisProportional Hazards ModelsRNA Splicing FactorsRNA, MessengerConceptsDisease-free survivalImmune cell infiltrationM6A regulatorsCRC patientsCRC casesCell infiltrationMRNA expressionWorse overall survivalN6-methyladenosine regulatorsMicrosatellite instability statusMessenger RNA expressionCancer Genome AtlasOverall survivalColorectal cancerCRC tissuesDatabase studyImmune functionInstability statusColon tissuesRole of m6AGene alterationsRNA expressionCRCGenome AtlasGenetic mutations
2018
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018, 9: 1793. PMID: 29728604, PMCID: PMC5935683, DOI: 10.1038/s41467-018-04278-6.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesLiver metastasesColorectal cancerOligometastatic colorectal cancerMetastatic colorectal cancerHigh-risk patientsSubset of patientsClinical risk stratificationTreatment of metastasesAngiogenic signatureVEGFA amplificationOligometastatic stateOverall survivalFavorable survivalRisk stratificationAdverse outcomesMetastatic cancerMolecular subtypesFocal therapyMetastasisPatientsMetastatic virulenceMolecular subtypingRobust subtypesCancer
2016
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapyColorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients
Khan SA, Morris M, Idrees K, Gimbel MI, Rosenberg S, Zeng Z, Li F, Gan G, Shia J, LaQuaglia MP, Paty PB. Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. Journal Of Pediatric Surgery 2016, 51: 1812-1817. PMID: 27558481, PMCID: PMC5312708, DOI: 10.1016/j.jpedsurg.2016.07.015.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdolescentAdultAge of OnsetAgedAged, 80 and overBiomarkers, TumorChildColorectal NeoplasmsDNA Mismatch RepairDNA Mutational AnalysisDNA, NeoplasmFemaleHumansMaleMicrosatellite InstabilityMiddle AgedMutationNeoplasm StagingRetrospective StudiesSurvival RateUnited StatesYoung AdultConceptsOnset colorectal cancerEarly-onset colorectal cancerAdult-onset patientsColorectal cancerEarly age onsetPoor prognosisMicrosatellite instabilityOnset patientsClinical dataEarly-age onset colorectal cancerMLH1/PMS2 lossAdult colorectal cancerAdult CRC patientsAdvanced stage presentationMismatch repair expressionHigh-grade cancerAge 30 yearsSpecific genetic subtypesCRC patientsFavorable survivalPMS2 lossGrade cancerBRAF mutationsTumor markersBRAFV600E mutation
2008
CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer
Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, Rosenberg S, Notterman DA, Ott J, Paty P, Barany F. CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer. Clinical Cancer Research 2008, 14: 6005-6013. PMID: 18829479, PMCID: PMC3268558, DOI: 10.1158/1078-0432.ccr-08-0216.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeColorectal cancerChromosomal aberrationsLigase detection reactionMicrosatellite instabilityRight-side colonPrimary colorectal cancerColorectal cancer developmentSporadic colorectal cancerSame study cohortCIMP-positive tumorsChromosomal instabilityStudy cohortAberrant promoter methylationPrimary tumorNormal mucosaBRAF mutationsIndependent markerPhenotype associatesDegree of aneuploidyBRAF mutation V600ETumor progressionIndependent molecular mechanismsCancerCancer developmentGenetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer
Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, Pincas H, Barany F, Offit K, LaQuaglia MP, Paty PB. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal Of Surgical Oncology 2008, 97: 621-625. PMID: 18381604, PMCID: PMC4381874, DOI: 10.1002/jso.20996.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerColorectal cancerMDM2 SNP309Age 30Germline variantsLi-Fraumeni kindredsP53 genePeripheral blood leukocytesNormal control populationP53 pathway genesFrequency of polymorphismsGermline TP53Blood leukocytesRare diseaseSNP309Control populationTissue availabilityPatientsConstitutional mutationsDisease susceptibilityCancerP53DiseaseGenetic variants